ClinicalTrials.gg
CompletedNCT01302041Updated Oct 2, 2018Results posted

A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy

A Phase 2 interventional study of Enzalutamide in Prostate Cancer, sponsored by Astellas Pharma Inc. Completed at 12 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-02.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
51st of 125
67 · median 52
Started
2011
with 3 others
Phase 2
65 of 125
8 open now
Registered
8th of 125
by date
Lead sponsor
7 of 125
Astellas Pharma Inc

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 51st largest by enrollment, is one of 4 that started in 2011, is one of 65 in phase 2, and was the 8th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • bone turnover
  • hormone-naïve
  • prostate specific antigen
  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a /adjuvant therapy)
  • Asymptomatic from prostate cancer
  • Non-castrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening
  • PSA ≥ 2 ng/mL at screening

Exclusion criteria

Exclusion Criteria:

Has previously or is currently receiving:

  • Hormonal therapy with intent to treat prostate cancer
  • Systemic
  • Chemotherapy with the intent to treat prostate cancer
  • Opiate analgesics for pain from prostate cancer
  • Radiation therapy for treatment of the primary tumor or
  • Has history of known or suspected brain or skull metastases or
  • Has history of seizure including febrile seizure or any condition that may predispose to seizure or history of loss of consciousness or
  • cardiovascular disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.

    Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Prostate-Specific Antigen (PSA) Response at Week 25

    A PSA response was defined as a decline from Baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to week 25 for any reason were treated as non-responders.

    Time frame: Baseline and Week 25

Secondary outcomes

  1. Number of Participants With Adverse Events

    Each adverse event (AE) was assessed by the investigator for causal relationship to the study drug; those deemed possibly or probably related to study drug are reported as drug regimen related AEs (DRRAEs). A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: * Resulted in death * Was life-threatening * Resulted in persistent or significant disability/incapacity * Resulted in congenital anomaly or birth defect * Required inpatient hospitalization or led to prolongation of hospitalization * Other medically important events.

    Time frame: From first dose of study drug up to 30 days after last dose of study drug; median duration of treatment of 1666.0 days (range of 52-2052)

  2. Percent Change From Baseline in PSA

    Time frame: Baseline and Weeks 25, 49, 97, 169 and Week 265 (End of Study)

  3. Percent Change From Baseline in Sex Hormone-Binding Globulin (SHBG)

    Time frame: Baseline and Weeks 25 and 49

  4. Percent Change From Baseline in Androstenedione

    Time frame: Baseline and Weeks 25 and 49

  5. Percent Change From Baseline in Dehydroepiandrosterone (DHEA)

    Time frame: Baseline and Weeks 25 and 49

  6. Percent Change From Baseline in Dihydrotestosterone (DHT)

    Time frame: Baseline and Week 25 and 49

  7. Percent Change From Baseline in Estradiol

    Time frame: Baseline and Weeks 25 and 49

  8. Percent Change From Baseline in Follicle-Stimulating Hormone (FSH)

    Time frame: Baseline and Weeks 25 and 49

  9. Percent Change From Baseline in Luteinizing Hormone (LH)

    Time frame: Baseline and Weeks 25 and 49

  10. Percent Change From Baseline in Prolactin

    Time frame: Baseline and Weeks 25 and 49

  11. Percent Change From Baseline in Total Testosterone

    Time frame: Baseline and Weeks 25 and 49

  12. Percent Change From Baseline in Free Testosterone

    Time frame: Baseline and Weeks 25 and 49

  13. Plasma Concentration of Enzalutamide at Pre-dose (Ctrough)

    Time frame: Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25

  14. Plasma Concentration of Enzalutamide Metabolite M2 at Pre-dose (Ctrough)

    Time frame: Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25

  15. Percentage of Participants With a PSA Response at Weeks 49, 97 and 169

    A PSA response was defined as a decline from baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to week 49, week 97 or week 169 for any reason were treated as non-responders.

    Time frame: Baseline and Weeks 49, 97 and 169

  16. Percentage of Participants With a 90% or Greater Reduction From Baseline in PSA Level

    Participants with unknown or missing PSA results at week 25 or who discontinued prior to week 25 were considered non-responders at week 25. Participants with unknown or missing PSA results at week 49, week 97 or week 169 were considered non-responders.

    Time frame: Baseline and Weeks 25, 49, 97 and 169

  17. Percentage of Participants With PSA ≤ 4 ng/ml

    Participants with unknown or missing PSA results at week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25. Participants with unknown or missing PSA results at week 49, 97 and 169 were considered non-responders.

    Time frame: Weeks 25, 49, 97 and 169

  18. Percentage of Participants With PSA ≤ 0.1 ng/ml

    Participants with unknown or missing PSA results at week 25 or who discontinued prior to week 25 were considered non-responders at week 25. Participants with unknown or missing PSA results at week 49, 97 or 169 were considered non-responders.

    Time frame: Weeks 25, 49, 97 and 169

  19. Maximum Decline From Baseline in PSA

    The maximum decline from Baseline in PSA was calculated as the largest reduction from Baseline in PSA level that occurred at any point after treatment start up to week 25 and up to and including the assessment made at the safety follow-up visit, divided by the PSA Baseline value and multiplied by 100, i.e., the maximum percent change from baseline.

    Time frame: Baseline to Week 25 and from Baseline up to the EOS date of 27 Apr 2017; median duration of treatment of 1666.0 days (range of 52-2052)

  20. Time to PSA Response

    Time to PSA response (PSA decline ≥ 80% from Baseline) is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 80% or greater was recorded. Time to response was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)

  21. Time to PSA Decline ≥ 90%

    Time to PSA decline ≥ 90% is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 90% or greater was recorded. Time to PSA decline ≥ 90% was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)

  22. Time to PSA ≤ 4 ng/ml

    Time to PSA ≤ 4 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 4 ng/ml or below was recorded. Time to PSA ≤ 4 ng/ml was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)

  23. Time to PSA ≤ 0.1 ng/ml

    Time to PSA ≤ 0.1 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 0.1 ng/ml or below was recorded. Time to PSA ≤ 0.1 ng/ml was estimated using the Kaplan-Meier method.

    Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)

  24. Time to PSA Progression

    Time to PSA progression is defined as the time interval from the first study drug dose to the first date of PSA progression. PSA progression is defined as a ≥ 25% increase in PSA with an absolute increase of ≥ 2 ng/mL above the nadir unless the PSA next measurement(s), if available, does not confirm the PSA progression.

    Time frame: From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)

  25. PSA Doubling Time

    PSA doubling time was to be calculated from the slope estimated from a linear regression of the natural log of PSA fitted on time, if the slope was positive. Since the slope was negative for all participants, PSA doubling time could not be calculated.

    Time frame: From Baseline to Week 25

07

Results

Posted Apr 6, 2016

Participant flow

This was a multinational, phase 2, open-label, single-arm, efficacy and safety study of oral enzalutamide in participants with prostate cancer who had noncastrate levels of testosterone at study entry.

Participant flow — Overall Study
MilestoneEnzalutamide
Started67
Treatment received67
Completed27
Not completed40
Withdrew: Death5
Withdrew: Withdrawal by subject4
Withdrew: Other-transitioned to 9785-cl-012329
Withdrew: Other-miscellaneous reason2

Outcome measures

PrimaryPercentage of Participants With a Prostate-Specific Antigen (PSA) Response at Week 25

A PSA response was defined as a decline from Baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to week 25 for any reason were treated as non-responders.

Time frame:
Baseline and Week 25
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Prostate-Specific Antigen (PSA) Response at Week 25
Percentage of ParticipantsEnzalutamide
Percentage of Participants With a Prostate-Specific Antigen (PSA) Response at Week 2592.5 (83.44 to 97.53)
SecondaryNumber of Participants With Adverse Events

Each adverse event (AE) was assessed by the investigator for causal relationship to the study drug; those deemed possibly or probably related to study drug are reported as drug regimen related AEs (DRRAEs). A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: * Resulted in death * Was life-threatening * Resulted in persistent or significant disability/incapacity * Resulted in congenital anomaly or birth defect * Required inpatient hospitalization or led to prolongation of hospitalization * Other medically important events.

Time frame:
From first dose of study drug up to 30 days after last dose of study drug; median duration of treatment of 1666.0 days (range of 52-2052)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsEnzalutamide
Any Adverse Events67
Drug Regimen Related Adverse Events65
Deaths5
Serious Adverse Events24
Drug Regimen Related Serious Adverse Events5
AEs Leading to Discontinuation of Study Drug14
DRRAEs Leading to Discontinuation of Study Drug7
SecondaryPercent Change From Baseline in PSA
Time frame:
Baseline and Weeks 25, 49, 97, 169 and Week 265 (End of Study)
Reported as:
Mean · Percent Change
Percent Change From Baseline in PSA
Percent ChangeEnzalutamide
Week 25-97.82 ± 5.744
Week 49-98.96 ± 2.767
Week 97-99.44 ± 1.114
Week 169-91.74 ± 27.808
Week 265 (End of Study)-0.70 ± 368.253
SecondaryPercent Change From Baseline in Sex Hormone-Binding Globulin (SHBG)
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Sex Hormone-Binding Globulin (SHBG)
Percent ChangeEnzalutamide
Week 25100.60 ± 49.362
Week 4988.45 ± 41.911
SecondaryPercent Change From Baseline in Androstenedione
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Androstenedione
Percent ChangeEnzalutamide
Week 2551.06 ± 59.367
Week 4949.94 ± 55.449
SecondaryPercent Change From Baseline in Dehydroepiandrosterone (DHEA)
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Dehydroepiandrosterone (DHEA)
Percent ChangeEnzalutamide
Week 259.59 ± 58.247
Week 4910.54 ± 54.864
SecondaryPercent Change From Baseline in Dihydrotestosterone (DHT)
Time frame:
Baseline and Week 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Dihydrotestosterone (DHT)
Percent ChangeEnzalutamide
Week 2551.72 ± 57.511
Week 4974.35 ± 101.451
SecondaryPercent Change From Baseline in Estradiol
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Estradiol
Percent ChangeEnzalutamide
Week 2571.69 ± 73.150
Week 4981.00 ± 82.811
SecondaryPercent Change From Baseline in Follicle-Stimulating Hormone (FSH)
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Follicle-Stimulating Hormone (FSH)
Percent ChangeEnzalutamide
Week 2546.99 ± 46.389
Week 4962.18 ± 78.371
SecondaryPercent Change From Baseline in Luteinizing Hormone (LH)
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Luteinizing Hormone (LH)
Percent ChangeEnzalutamide
Week 25184.66 ± 120.683
Week 49215.18 ± 163.732
SecondaryPercent Change From Baseline in Prolactin
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Prolactin
Percent ChangeEnzalutamide
Week 2516.79 ± 45.497
Week 499.64 ± 30.003
SecondaryPercent Change From Baseline in Total Testosterone
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Total Testosterone
Percent ChangeEnzalutamide
Week 25114.29 ± 73.692
Week 49101.73 ± 76.070
SecondaryPercent Change From Baseline in Free Testosterone
Time frame:
Baseline and Weeks 25 and 49
Reported as:
Mean · Percent Change
Percent Change From Baseline in Free Testosterone
Percent ChangeEnzalutamide
Week 2546.39 ± 59.551
Week 4943.74 ± 55.721
SecondaryPlasma Concentration of Enzalutamide at Pre-dose (Ctrough)
Time frame:
Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25
Reported as:
Mean · μg/mL
Plasma Concentration of Enzalutamide at Pre-dose (Ctrough)
μg/mLEnzalutamide
Week 27.225 ± 1.8050
Week 310.559 ± 2.1967
Week 411.838 ± 2.4605
Week 512.161 ± 2.8496
Week 911.606 ± 3.0084
Week 1311.868 ± 2.9760
Week 2111.224 ± 2.8899
Week 2511.668 ± 2.7624
SecondaryPlasma Concentration of Enzalutamide Metabolite M2 at Pre-dose (Ctrough)
Time frame:
Pre-dose at Weeks 2, 3, 4, 5, 9, 13, 21 and 25
Reported as:
Mean · μg/mL
Plasma Concentration of Enzalutamide Metabolite M2 at Pre-dose (Ctrough)
μg/mLEnzalutamide
Week 22.527 ± 1.0440
Week 35.344 ± 1.7079
Week 48.182 ± 2.4366
Week 59.962 ± 2.7584
Week 912.128 ± 3.1262
Week 1312.780 ± 3.2564
Week 2111.717 ± 2.9502
Week 2512.146 ± 2.5845
SecondaryPercentage of Participants With a PSA Response at Weeks 49, 97 and 169

A PSA response was defined as a decline from baseline in PSA level of 80% or greater. Blood samples for PSA were collected and analyzed at a central laboratory. Participants with an unknown or missing response or who discontinued prior to week 49, week 97 or week 169 for any reason were treated as non-responders.

Time frame:
Baseline and Weeks 49, 97 and 169
Reported as:
Number · Percentage of Participants
Percentage of Participants With a PSA Response at Weeks 49, 97 and 169
Percentage of ParticipantsEnzalutamide
Week 4980.6 (69.11 to 89.24)
Week 9767.2 (54.60 to 78.15)
Week 16956.7 (44.04 to 68.78)
SecondaryPercentage of Participants With a 90% or Greater Reduction From Baseline in PSA Level

Participants with unknown or missing PSA results at week 25 or who discontinued prior to week 25 were considered non-responders at week 25. Participants with unknown or missing PSA results at week 49, week 97 or week 169 were considered non-responders.

Time frame:
Baseline and Weeks 25, 49, 97 and 169
Reported as:
Number · Percentage of Participants
Percentage of Participants With a 90% or Greater Reduction From Baseline in PSA Level
Percentage of ParticipantsEnzalutamide
Week 2591.0
Week 4998.1
Week 97100.0
Week 16988.1
SecondaryPercentage of Participants With PSA ≤ 4 ng/ml

Participants with unknown or missing PSA results at week 25 or who discontinued prior to Week 25 were considered non-responders at Week 25. Participants with unknown or missing PSA results at week 49, 97 and 169 were considered non-responders.

Time frame:
Weeks 25, 49, 97 and 169
Reported as:
Number · Percentage of Participants
Percentage of Participants With PSA ≤ 4 ng/ml
Percentage of ParticipantsEnzalutamide
Week 2592.5
Week 4994.4
Week 97100.0
Week 16995.2
SecondaryPercentage of Participants With PSA ≤ 0.1 ng/ml

Participants with unknown or missing PSA results at week 25 or who discontinued prior to week 25 were considered non-responders at week 25. Participants with unknown or missing PSA results at week 49, 97 or 169 were considered non-responders.

Time frame:
Weeks 25, 49, 97 and 169
Reported as:
Number · Percentage of Participants
Percentage of Participants With PSA ≤ 0.1 ng/ml
Percentage of ParticipantsEnzalutamide
Week 2544.8
Week 4963.0
Week 9773.3
Week 16961.9
SecondaryMaximum Decline From Baseline in PSA

The maximum decline from Baseline in PSA was calculated as the largest reduction from Baseline in PSA level that occurred at any point after treatment start up to week 25 and up to and including the assessment made at the safety follow-up visit, divided by the PSA Baseline value and multiplied by 100, i.e., the maximum percent change from baseline.

Time frame:
Baseline to Week 25 and from Baseline up to the EOS date of 27 Apr 2017; median duration of treatment of 1666.0 days (range of 52-2052)
Reported as:
Mean · Percent Change
Maximum Decline From Baseline in PSA
Percent ChangeEnzalutamide
Maximum Decline by Week 25-98.32 ± 2.880
Maximum Decline by EOS-99.10 ± 2.659
SecondaryTime to PSA Response

Time to PSA response (PSA decline ≥ 80% from Baseline) is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 80% or greater was recorded. Time to response was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Reported as:
Median · Days
Time to PSA Response
DaysEnzalutamide
Time to PSA Response29 (28 to 31)
SecondaryTime to PSA Decline ≥ 90%

Time to PSA decline ≥ 90% is defined as the time interval from the first study drug dose to the first date a decline from Baseline in PSA level of 90% or greater was recorded. Time to PSA decline ≥ 90% was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Reported as:
Median · Days
Time to PSA Decline ≥ 90%
DaysEnzalutamide
Time to PSA Decline ≥ 90%55 (29 to 57)
SecondaryTime to PSA ≤ 4 ng/ml

Time to PSA ≤ 4 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 4 ng/ml or below was recorded. Time to PSA ≤ 4 ng/ml was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Reported as:
Median · Days
Time to PSA ≤ 4 ng/ml
DaysEnzalutamide
Time to PSA ≤ 4 ng/ml29 (9 to 57)
SecondaryTime to PSA ≤ 0.1 ng/ml

Time to PSA ≤ 0.1 ng/ml is defined as the time interval from the first study drug dose to the first date a decline in PSA to a result of 0.1 ng/ml or below was recorded. Time to PSA ≤ 0.1 ng/ml was estimated using the Kaplan-Meier method.

Time frame:
From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Reported as:
Median · Days
Time to PSA ≤ 0.1 ng/ml
DaysEnzalutamide
Time to PSA ≤ 0.1 ng/ml168 (58 to 581)
SecondaryTime to PSA Progression

Time to PSA progression is defined as the time interval from the first study drug dose to the first date of PSA progression. PSA progression is defined as a ≥ 25% increase in PSA with an absolute increase of ≥ 2 ng/mL above the nadir unless the PSA next measurement(s), if available, does not confirm the PSA progression.

Time frame:
From first dose until the EOS date of 27-Apr-2017; median duration of treatment of 1666.0 days (range of 52-2052)
Reported as:
Median · Days
Time to PSA Progression
DaysEnzalutamide
Time to PSA ProgressionNA (NA to NA)
SecondaryPSA Doubling Time

PSA doubling time was to be calculated from the slope estimated from a linear regression of the natural log of PSA fitted on time, if the slope was positive. Since the slope was negative for all participants, PSA doubling time could not be calculated.

Time frame:
From Baseline to Week 25

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of study drug up to 30 days after last dose of study drug; median duration of treatment of 1666.0 days (range of 52-2052). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide5/67 (7.5%)24/67 (35.8%)66/67 (98.5%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventEnzalutamide
Atrial fibrillationCardiac disorders4/67
Angina pectorisCardiac disorders2/67
PneumoniaInfections and infestations2/67
SyncopeNervous system disorders2/67
Urinary retentionRenal and urinary disorders2/67
LymphadenopathyBlood and lymphatic system disorders1/67
Acute myocardial infarctionCardiac disorders1/67
ArrhythmiaCardiac disorders1/67
BradycardiaCardiac disorders1/67
Cardiac arrestCardiac disorders1/67
Most frequent other events
Showing 10 of 31
Most frequent other events
EventEnzalutamide
GynaecomastiaReproductive system and breast disorders36/67
FatigueGeneral disorders28/67
HypertensionVascular disorders17/67
Hot flushVascular disorders15/67
Nipple painReproductive system and breast disorders13/67
DiarrhoeaGastrointestinal disorders11/67
NauseaGastrointestinal disorders11/67
Back painMusculoskeletal and connective tissue disorders10/67
ConstipationGastrointestinal disorders9/67
Oedema peripheralGeneral disorders8/67

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Enzalutamide
Median73.0 (48 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide
Female0
Male67
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Enzalutamide
Median26.17 (20.8 to 39.7)
Prostate Specific Antigen (PSA)
Prostate Specific Antigen (PSA)(ng/mL)Enzalutamide
Median18.2 ± 102.990
Duration of Prostate Cancer
Duration of Prostate Cancer(years)Enzalutamide
Median1.0 (0 to 16)
Total Gleason Score at Initial Diagnosis
Total Gleason Score at Initial Diagnosis(Participants)Enzalutamide
41
55
610
734
87
96
103
Unknown1
Clinical Tumor Stage (T) at Initial Diagnosis
Clinical Tumor Stage (T) at Initial Diagnosis(Participants)Enzalutamide
TX: Primary tumor cannot be assessed1
T0: No evidence of primary tumor1
T1: Tumor neither palpable or visible by imaging9
T2: Tumor confined within the prostate31
T3: Tumor extends through the prostatic capsule18
T4: Tumor is fixed or invades adjacent structures1
Unknown6
Clinical Lymph Node Stage (N) at Initial Diagnosis
Clinical Lymph Node Stage (N) at Initial Diagnosis(Participants)Enzalutamide
NX: Regional lymph nodes were not assessed24
N0: No regional lymph node metastasis22
N1: Metastasis in regional lymph node(s)6
Unknown15

4 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • Site BE1003
    Brussels, 1090, Belgium
  • Site BE1001
    Brussels, 1200, Belgium
  • Site BE1002
    Kortrijk, 8500, Belgium
  • Site BE1005
    Leuven, 3000, Belgium
  • Site CZ3006
    Olomouc, 77520, Czechia
  • Site CZ3002
    Praha 6, 16000, Czechia
  • Site DK4001
    Aarhus N, 8200, Denmark
  • Site DK4004
    Copenhagen, DK-2100, Denmark
  • Site DK4002
    Herlev, 2730, Denmark
  • Site DE5005
    Aachen, 51074, Germany
  • Site DE5007
    Bonn, 53111, Germany
  • Site DE5003
    Hannover, 30625, Germany
09

References and documents

Publications

  • Trump D. Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Universite Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik fur Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14]. Urol Oncol. 2016 May;34(5):248-9. doi: 10.1016/j.urolonc.2015.03.012. Epub 2015 Apr 30. PubMed 25937426 ↗
  • Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Baron B, Hirmand M, Smith MR. Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. Eur Urol. 2015 Nov;68(5):787-94. doi: 10.1016/j.eururo.2015.01.027. Epub 2015 Feb 14. PubMed 25687533 ↗
  • Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014 May;15(6):592-600. doi: 10.1016/S1470-2045(14)70129-9. Epub 2014 Apr 14. PubMed 24739897 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Jul 2012, 14 months.

Results were first posted in Apr 2016, 3 years 8 months after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 14 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2011
First posted
Feb 23, 2011
StartActual
May 6, 2011
Primary completionActual
Jul 29, 2012
CompletionActual
Apr 27, 2017
Results first posted
Apr 6, 2016
Last update
Oct 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01302041
Collaborators
Medivation, Inc.
Responsible party
Sponsor
First posted
Feb 23, 2011
Start date
May 6, 2011
Primary completion
Jul 29, 2012
Completion
Apr 27, 2017
Results posted
Apr 6, 2016
Last update
Oct 2, 2018

Study contacts

Use Central Contact
study director · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion